Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2022-05-04 Regulatory Filings
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Upcoming Investor Conferences
Regulatory Filings Classification · 1% confidence The document is a press release announcing the company's participation in upcoming investor conferences. It does not contain financial results, board changes, or specific regulatory filings, but rather serves as a general corporate announcement regarding investor relations activities. As it does not fit into more specific categories like 'Investor Presentation' (which would be the actual slides) or 'Earnings Release', it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement distributed via the RNS/Reach service.
2022-05-04 English
FORM 10-K/A
Annual Report FY 2021
2022-04-29 English
Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from MaxCyte, Inc. regarding the issuance of new common stock following the exercise of share options and the subsequent update to the total voting rights (denominator for shareholder notifications). This falls under the category of share capital changes and issuance, which is classified as SHA (Share Issue/Capital Change).
2022-04-29 English
Inducement Grants Under Nasdaq Listing Rule 5635
Regulatory Filings Classification · 1% confidence The document is an RNS announcement from MaxCyte, Inc. regarding the grant of stock options as employment inducements to new employees, including the Chief Scientific Officer. This falls under the category of share-based compensation or capital changes related to equity issuance/grants. Since it specifically details the issuance of stock options as an inducement, it is best classified as a share issue/capital change announcement.
2022-04-19 English
Departure of CFO and Preliminary Q1 2022 Revenue
Regulatory Filings Classification · 1% confidence The document is a press release distributed via RNS (Regulatory News Service) announcing two primary events: the resignation/appointment of a CFO (Management change) and preliminary Q1 2022 revenue figures (Earnings release). Since the document covers both management changes and preliminary financial results, and is formatted as a standard corporate news announcement, it fits best under the 'Earnings Release' (ER) category as the primary driver of the disclosure is the financial performance update, or alternatively 'Management Information' (MANG). Given the prominence of the preliminary revenue figures, ER is the most appropriate classification.
2022-04-13 English
FORM 8-K
Regulatory Filings
2022-04-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.